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Abstract
The TSA Opal multiplex immunohistochemistry (mIHC) protocol (PerkinElmer) has been
used to characterize immune infiltration in human cancers. This technique allows multiple
biomarkers to be simultaneously stained in a single tissue section, which helps to elucidate
the spatial relationship among individual cell types. We developed and optimized two
improved mIHC protocols for a 7-color panel containing 6 biomarkers (CD3, CD8, CD163,
PD-L1, FoxP3, and cytokeratin (CK)) and DAPI. The only difference between these two pro-
tocols was the staining sequence of those 6 biomarkers as the first sequence is PD-L1/
CD163/CD8/CK/CD3/FoxP3/DAPI and the second sequence is FoxP3/CD163/CD8/CK/
CD3/PD-L1/DAPI. By comparing PD-L1/FoxP3 staining in mIHC and singleplex PD-L1/
FoxP3 staining on the adjacent slide, we demonstrated that the staining sequence does not
affect the staining intensity of individual biomarkers as long as a proper antigen retrieval
method was used. Our study suggests that use of an antigen retrieval buffer with higher pH
value (such as Tris-EDTA pH9.0) than that of the stripping buffers (such as citrate buffer
pH6.0) is helpful when using this advanced mIHC method to develop panels with multiple
biomarkers. Otherwise, individual biomarkers may exhibit different intensities when the
staining sequence is changed. By using this protocol, we characterized immune infiltration
and PD-L1 expression in head and neck squamous cell carcinoma (HNSCC), breast cancer
(BCa), and non-small cell lung cancer (NSCLC) specimens. We observed a statistically sig-
nificant increase in CD3+ cell populations within the stroma of NSCLC as compared to BCa
and increased PD-L1+ tumor cells in HNSCC as opposed to BCa.
Introduction
Cancer immunotherapy, such as checkpoint blockade, represents a powerful approach for the
treatment of different types of human cancer such as melanoma, non-small cell lung cancer
(NSCLC), and renal cell carcinoma, among others [1–5]. In addition, the immune profile pres-
ent within each patient’s tumor has been used as a valuable reference for prognosis of long-
term outcomes and survival across different types of cancer [6]. These traditional
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(chromogenic) IHC-based approaches have provided valuable insight into the role of immune
infiltration in directing subsequent clinical response to treatment. More recently, multiplexed
immunohistochemistry (mIHC)-based analysis, compared with other cutting-edge technolo-
gies, has been shown to provide unique insight into the spatial relationships among cells within
the complex tumor microenvironment (TME) including infiltrating immune cells, cancer
cells, and stromal cells [7, 8].
Using the TSA Opal mIHC protocol [9], multiple immune biomarkers can be detected in a
single tissue section through sequential staining, regardless of the species of the primary anti-
bodies. Therefore, this protocol can overcome the hurdle of conventional mIHC, which nor-
mally uses a cocktail of primary antibodies raised in different species of animals. In this
protocol, heat-treated stripping in citrate buffer pH6.0 is used to remove primary and second-
ary antibodies before staining the next biomarker, but not TSA-conjugated fluorescent mole-
cules, which was demonstrated in human melanoma tissue [10]. Since antigen retrieval was
found to significantly improve IHC in formalin-fixed paraffin-embedded (FFPE) tissue [11],
citrate buffer pH6.0 has been widely used in heat-induced antigen retrieval (HIAR), even
though Tris-HCl shows better results at higher pH [12]. The stripping ability of citrate buffer
has been addressed in sequentially-stained mIHC specimens [9, 13–15]. Notably, it has caused
some confusion in developing mIHC protocols using the TSA Opal kit. Indeed, few if any
studies have addressed the utility of this buffer for antigen retrieval versus its use as a stripping
buffer for mIHC. This is particularly critical when multiple biomarkers in a single panel
require different antigen retrieval methods, such as Tris-EDTA pH9.0 versus citrate buffer
pH6.0, based upon the vendor’s recommendations provided with each antibody. Importantly,
how to choose or balance antigen retrieval methods for an entire panel with multiple biomark-
ers has not been addressed.
Automated IHC has been widely used in the in vitro diagnostic field as it provides efficiency
and consistency for IHC staining. Previous studies have shown that heating is the most impor-
tant factor, in terms of antigen retrieval [16, 17]. An optimal result of HIAR is correlated with
the heating temperature (T) and the heating time (t), which means the heating condition is
decided by “T x t” [12, 18, 19]. To get consistent IHC results, antigen retrieval using an auto-
stainer requires lower temperatures (<100˚C), but much longer heating times, which keeps
the antigen retrieval buffer from boiling and potentially drying out the tissue section. This
includes the FDA-approved Ventana PD-L1(SP263) Assay running on the VENTANA Bench-
Mark ULTRA (https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160046c.pdf) and many
other clinically-approved IHC tests conducted on autostainers (https://www.atlasantibodies.
com/globalassets/protocols/ihc_ventana_protocol.pdf).
Most research labs perform manual staining and HIAR using a microwave oven or pressure
cooker, in which the tissue sections are immersed in a large volume of the antigen retrieval
buffer, which are capable of generating higher temperatures (�100˚C) and shorter heating
times. Other considerations include the time and temperature of primary and secondary anti-
body incubation and signal development. For some autostainers, such as the Ventana Bench-
ark, antibody incubation at 37˚C (rather than room temperature) is preferred. While some
reports have combined automation and manual staining for mIHC, these protocols can be dif-
ficult to follow as the working conditions of the two approaches are somewhat distinct.
In the current study, we have developed two mIHC protocols with different staining
sequences. In both of the protocols, Tris-EDTA pH9.0 has been used for retrieving antigens.
We started from antibody validation, optimization, and staining all biomarkers sequentially to
forming a multiplex panel by manual staining. These protocols maintain tissue integrity by
using H2O2 to kill exogenous horse radish peroxidase (HRP) activity between two different
species of primary antibodies instead of heat-treated stripping using citrate buffer pH6.0 in a
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microwave oven. In addition, we validated this protocol across multiple cancer types including
human head and neck squamous cell carcinoma (HNSCC), breast cancer (BCa), and non-
small cell lung cancer (NSCLC) (FFPE slides) and were able to generate consistent and robust
staining results for each individual biomarker across each tumor type. Together, these data
provide a simple and effective method to optimize mIHC panels for assessment of immune
infiltration in human cancer tissues.
Materials and methods
Antibody validation and optimization
Human FFPE tonsil tissue blocks were provided by Department of Pathology at Providence
Portland Medical Center (Portland, Oregon). 4μm thin sections were cut on a Leica RM2235
microtome in the IHC Core Lab of the Earle A. Chiles Research Institute (Portland, Oregon).
Deparaffinization of tissue sections was done through xylenes. Rehydration was done through
decreasing graded alcohol. 1X Tris-EDTA (10mM Tris Base, 1mM EDTA, pH9.0) and 0.1M
Sodium Citrate pH6.0 were used for retrieving antigens in a microwave oven and a hydropho-
bic pen was used to circle tissue sections. Endogenous peroxidase was blocked by 3% H2O2 for
15 min at room temperature (RT). Before primary antibody incubation, tissue sections were
blocked with blocking/antibody diluent (ARD1001EA, PerkinElmer) for 10 min at RT. The tis-
sue sections were incubated with anti-PD-L1 (E1L3N, Cell Signaling), anti-CD163 (MRQ-26,
Roche/Ventana), anti-CD8 (SP16, Spring Biosciences), anti-cytokeratin (CK) (AE1/AE3,
Dako), anti-CD3 (SP7, Genetex), and anti-FoxP3 (236A/E7, Abcam) respectively at 4˚C, over-
night in a staining tray (see Table 1 for additional details). The next morning, tissue sections
were washed in 1X TBST and then incubated with secondary antibody MACH2 Rb HRP-Poly-
mer (RHRP520H, Biocare Medical) or MACH2 M HRP-Polymer (MHRP520H, Biocare Med-
ical) in terms of the species of the primary antibody for 30min at RT. Followed by a brief wash,
tissue sections were incubated with DAB (SK-4105, Vector) for about 3 min at RT. Counter-
staining was done with hematoxylin (3801562, Leica) for 45 seconds followed by rinsing and
bluing in flowing tap water for about 2 min. Then, tissue sections were dehydrated through
increasing graded alcohol and cleared in xylenes. The slides were mounted with cytoseal 60
(8310–4, Thermo Scientific) and dried in the chemical hood.
Opal singleplex IHC validation
Six pairs (sets) of adjacent human FFPE tonsil sections were used for comparing chromogenic
and fluorescent staining in parallel. Deparaffinization of tissue sections was done through
xylenes and rehydration through decreasing graded alcohol. 1X Tris-EDTA pH9.0 was used for
antigen retrieval in a microwave oven. A hydrophobic pen was used to circle tissue sections and
endogenous peroxidase was blocked with 3% H2O2 for 15 min at RT. Before primary antibody
incubation, the tissue sections were blocked with blocking/antibody diluent (ARD1001EA) for
Table 1. Antibodies tested for developing the mIHC protocols.
Antibody Clone Species Titration Fluorophore Vendor
PD-L1 E1L3N Rabbit 1:1600 Opal690/Opal520 Cell Signaling
CD163 MRQ-26 Mouse 1:4 Opal620 Roche/Ventana
CD8 SP16 Rabbit 1:400 Opal650 Spring Biosciences
CD3 SP7 Rabbit 1:600 Opal540 Genetex
Foxp3 236A/E7 Mouse 1:400 Opal520/Opal690 Abcam
Cytokeratin AE1/AE3 Mouse 1:3000 Opal570 Dako
https://doi.org/10.1371/journal.pone.0247238.t001
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10 min at RT. Working dilutions for anti-PD-L1, anti-CD163, anti-CD8, anti-CK, anti-CD3,
and anti-FoxP3 were 1:1600, 1:4, 1:400, 1:3000, 1:600, and 1:400, respectively.
For Opal fluorescent staining, tissue sections were incubated with primary antibodies at RT
in a shaking stain tray. Incubation times for anti-PD-L1, anti-CD163, anti-CD8, anti-CK, anti-
CD3, and anti-FoxP3 were 30, 20, 30, 20, 15, and 30 min, respectively. After a brief wash, tissue
sections were incubated with MACH2 Rb HRP-Polymer (RHRP520H) or MACH2 M
HRP-Polymer (MHRP520H) for 10 min at RT. A quick wash in 1X TBST was followed by
incubation with Opal690 (1:200), Opal620 (1:400), Opal650 (1:200), Opal570 (1:400), Opal540
(1:200), and Opal520 (1:400), respectively, for 10 min at RT. Counter stain was done with
DAPI (1 drop of DAPI solution into 0.5ml of TBST, PerkinElmer) for 5 min at RT. After a
quick wash, the slides were mounted with Prolong Diamond Antifade Mountant (p36970,
Thermofisher).
For chromogenic staining, tissue sections were incubated with primary antibodies at 4˚C
overnight in a staining tray. Next, tissue sections were washed in 1X TBST before they were
incubated with MACH2 Rb HRP-Polymer (RHRP520H) or MACH2 M HRP-Polymer
(MHRP520H) for 30 min at RT. Followed by brief wash, tissue sections were incubated with
DAB (SK-4105) for about 3 min at RT. Counter staining was done in hematoxylin for 45 sec
followed by rinsing and bluing in flowing tap water for 2 min. Then the tissue sections were
dehydrated through increasing graded alcohol and cleared in xylenes. The slides were
mounted with cytoseal 60 (8310–4) and dried in the chemical hood.
For generation of the spectral library, single biomarker staining only (without DAPI) was
performed on serial FFPE tonsil sections. DAPI stained only slides (tonsil) were prepared at
the same time. All scale bars represent 100 μm.
Slide imaging—Vectra 3 automated quantitative pathology system
Before scanning the 7 color mIHC slides, optimal scanning protocols were created by optimiz-
ing the exposure time for each filter cube. Each mIHC slide requires one optimized scanning
protocol. The filter cubes were selected based upon the fluorophores. A 10x objective lens was
used for whole slide scans, while a 20x objective lens was used for the multispectral images
(MSI’s). To obtain images for establishing the spectral library, snapshots were taken from each
single biomarker-stained slide. The snapshots for DAPI-stained and unstained slides were
taken through the DAPI filter cube. 20 MSI images/ROIs were taken from each control (tonsil)
slide. 10–15 MSI images/ROIs were taken from each patient (tumor) slide.
Quantification analysis: InForm advanced image analysis software and
QuPath quantitative pathology & bioimage analysis
The spectral library was generated using the snapshots of the single biomarker-stained slides.
The spectra was selected based upon the fluorophores. Composite images were generated by
extracting unmixed signals using the spectral library. Snapshots of unstained slides were used
for removing background caused by tissue fixation. Quantification analysis was performed by
following the standard procedure which includes Tissue Segmentation, Cell Segmentation, Phe-
notyping, Scoring, and Export. Tissue segmentation was not applied to tonsil tissue. The thresh-
old of biomarker intensity was determind by a Board-certified Pathologist (Dr. Yaping Wu,
MD). The percentage of positive cells from each MSI image/ROI was used for the analysis and
1-way ANOVA and Linear Regression were used for statistical analysis. Whole slide quantita-
tive analysis was performed on singleplex chromogenic and fluorescent tonsil tissue sections
using QuPath Quantitative Pathology & Bioimage Analysis [16, 17, 20]. Average and Standard
Deviation and Linear Regression were used for statistical analysis using Microsoft Excel.
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Multiplexed immunohistochemistry
Tissue fixation, embedding, and sectioning. Human cancer tissue fixation, embedding,
sectioning, and H&E staining were done using standard protocols in the Histopathology Lab
at Providence Portland Medical Center. Human tonsil tissue blocks were provided by the His-
topathology Lab and sectioning was done in the EACRI IHC Core Lab.
Deparaffinization, rehydration, and antigen retrieval. Human FFPE tissue sections
were deparaffinized with xylenes, rehydrated through graded alcohols, and rinsed with diH2O
and 1X TBS by following standard protocols. Antigen retrieval was performed in Tris-EDTA
pH9.0 in a microwave oven for 15 min. Retrieval buffer was refilled every 5 min. The tissue
sections were cooled down on the bench top for 30 min.
Blocking endogenous enzyme and background. After briefly washing in diH2O and 1X
TBS, the tissue sections were circled with a hydrophobic pen. Endogenous HRP was quenched
by incubating with 3% H2O2 for 15 min at RT, then tissue sections were rinsed with diH2O
and 1X TBS and then blocked with blocking/antibody diluent (ARD1001EA) for 10 min at
RT.
Staining. The incubation of primary and secondary antibodies and fluorophores were
done in a slide staining tray with shaking at RT.
I. Protocol 1. Staining sequence: PD-L1, CD163, CD8, CK, CD3, FoxP3, and DAPI
First staining cycle
First biomarker: PD-L1 staining. Tissue sections were incubated with anti-PD-L1 (1:1600,
E1L3N) for 30 min. After a brief wash with 1X TBST, slides were incubated with MACH2 Rb
HRP-Polymer (RHRP520H) for 10 min. After a brief wash with 1X TBST, Opal690 (1:200)
was added and incubated for 10 min.
Quenching exogenous HRP. After the tissue sections were briefly washed in 1X TBST, exoge-
nous HRP was quenched by incubating with 3% H2O2 for 20 min at RT. After the tissue sec-
tions were rinsed with diH2O, they were transferred to 1X TBST.
Second biomarker: CD163 staining. The tissue sections were incubated with anti-CD163
(1:4, MRQ-26) for 20 min. A brief wash with 1X TBST was followed by incubating with
MACH2 M HRP-Polymer (MHRP520H) for 10 min. After a brief wash with 1X TBST, the sec-
tions were incubated with Opal620 (1:400) for 10 min.
Stripping. After a quick wash was done in 1X TBST, the stripping was performed for 15 min
in 0.1M sodium citrate pH6.0 in a 24-slot plastic staining dish in a microwave oven. The strip-
ping buffer was refilled every 5 min. The section slides were cooled down on the bench top for
30 min.
Second staining cycle
Third biomarker: CD8 staining. The tissue sections were blocked with blocking/antibody
diluent (ARD1001EA) for 10 min at RT followed by incubating with anti-CD8 (1:400, SP16)
for 30 min. A brief wash with 1X TBST was followed by incubation with MACH2 Rb HRP-Po-
lymer (RHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sections were incu-
bated with Opal650 (1:200) for 10 min.
Quenching exogenous HRP. The exogenous HRP was quenched by 3% H2O2 for 20 min at
RT after a brief wash with 1X TBST. After the tissue sections were rinsed with diH2O, they
were transferred to TBST.
Fourth biomarker: Anti-human CK staining. The tissue sections were incubated with anti-
human CK (1:3000, AE1/AE3) for 20 min. A brief wash with 1X TBST was followed by incuba-
tion with MACH2 M HRP-Polymer (MHRP520H) for 10 min. After a brief wash with1X
TBST, the tissue sections were incubated with Opal570 (1:400) for 10 min.
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Stripping. After washing in 1X TBST, stripping was performed for 15 min in 0.1M sodium
citrate pH6.0 in a 24-slot plastic staining dish in a microwave oven. The stripping buffer was
refilled every 5 min and slides were cooled down on the bench top for 30 min.
Third staining cycle
Fifth biomarker: CD3 staining. The tissue sections were blocked with blocking/antibody dil-
uent (ARD1001EA) for 10 min at RT followed by incubating with anti-CD3 (1:600) for 15
min. A brief wash with 1X TBST was followed by tissue incubation with MACH2 Rb HRP-Po-
lymer (RHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sections were incu-
bated with Opal540 (1:200) for 10 min.
Quenching exogenous HRP. After a brief wash with 1X TBST, the exogenous HRP was
quenched by 3% H2O2 for 30 min at RT. After the tissue sections were rinsed with diH2O, they
were transferred to 1X TBST.
Sixth biomarker: FoxP3 staining. The tissue sections were incubated with anti-FoxP3 (1:400,
236A/E7) for 30 min. A brief wash with 1X TBST was followed by tissue incubation with MACH2
M HRP-Polymer (MHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sections
were incubated with Opal520 (1:400) for 10 min. Then a quick wash was done in 1X TBST.
Counterstain and coverslip mounting. After the sections were incubated with DAPI (1 drop
of DAPI solution into 0.5ml of TBST) for 5 min at RT, the slides were mounted with Prolong
Diamond Antifade Mountant (p36970).
II. Protocol 2. Staining sequence: FoxP3, CD163, CD8, CK, CD3, PD-L1, and DAPI
First biomarker: FoxP3 staining. The tissue sections were incubated with anti-FoxP3 (1:400,
236A/E7) for 30 min. A brief wash with 1x TBST was followed by tissue incubation with MACH2
M HRP-Polymer (MHRP520H) for 10 min. After a brief wash with 1x TBST, the tissue sections
were incubated with Opal690 (1:400) for 10 min. Then quick wash was done in 1X TBST.
Stripping. After a quick wash was done in 1X TBST, the stripping was performed for 15 min
in 0.1M sodium citrate pH6.0 in a 24-slot plastic staining dish in a microwave oven. The strip-
ping buffer was refilled every 5 min. The section slides were cooled down on the bench top for
30 min.
Second biomarker: CD163 staining. The tissue sections were blocked with blocking/antibody
diluent (ARD1001EA) for 10 min at RT followed by incubating with anti-CD163 (1:4, MRQ-
26) for 20 min. A brief wash with 1X TBST was followed by incubation with MACH2 M
HRP-Polymer (MHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sections
were incubated with Opal620 (1:400) for 10 min.
Quenching exogenous HRP. After a brief wash with 1X TBST, the exogenous HRP was
quenched by 3% H2O2 for 20 min at RT. After the tissue sections were rinsed with diH2O, they
were transferred to 1X TBST.
Third biomarker: CD8 staining. The tissue sections were incubated with anti-CD8 (1:400,
SP16) for 30 min. A brief wash with 1X TBST was followed by incubating with MACH2 Rb
HRP-Polymer (RHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sections
were incubated with Opal650 (1:200) for 10 min.
Stripping. After a quick wash was done in 1X TBST, the stripping was performed for 15 min in
0.1M sodium citrate pH6.0 in a 24-slot plastic staining dish in a microwave oven. The stripping
buffer was refilled every 5 min. The section slides were cooled down on the bench top for 30 min.
Fourth biomarker: CK staining. The tissue sections were blocked with blocking/antibody
diluent (ARD1001EA) for 10 min at RT followed by incubating with anti-human-CK (1:3000,
AE1/AE3) for 20 min. A brief wash with 1X TBST was followed by incubating with MACH2
M HRP-Polymer (MHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sec-
tions were incubated with Opal570 (1:400) for 10 min.
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Quenching exogenous HRP. After a brief wash with 1X TBST, the exogenous HRP was
quenched by 3% H2O2 for 20 min at RT. After the tissue sections were rinsed with diH2O, they
were transferred to 1X TBST.
Fifth biomarker: CD3 staining. The tissue sections were incubated with anti-CD3 (1:600,
SP7) for 15 min. A brief wash with 1X TBST was followed by incubating with MACH2 Rb
HRP-Polymer (RHRP520H) for 10 min. After a brief wash with 1X TBST, the tissue sections
were incubated with Opal540 (1:200) for 10 min.
Stripping. After a quick wash was done in 1X TBST, the stripping was performed for 15 min in
0.1M sodium citrate pH6.0 in a 24-slot plastic staining dish in a microwave oven. The stripping
buffer was refilled every 5 min. The section slides were cooled down on the bench top for 30 min.
Sixth biomarker: PD-L1 staining. The tissue sections were incubated with anti-PD-L1
(1:1600, E1L3N) for 30 min. A brief wash with 1X TBST was followed by tissue incubating
with MACH2 Rb HRP-Polymer (RHRP520H) for 10 min. After a brief wash with 1X TBST,
the tissue sections were incubated with Opal520 (1:200) for 10 min.
Counterstain and coverslip mounting. After the tissue sections were incubated with DAPI (1
drop of DAPI solution into 0.5ml of 1X TBST) for 5 min at RT. The slides were mounted with
Prolong Diamond Antifade Mountant (p36970).
Comparison of individual biomarkers in mIHC versus singleplex–stained
adjacent tissue slides
Two batches of human FFPE tonsil tissue slides were used, each containing three serial tissue
slides. The middle one in each batch was used for mIHC stain by following protocol 1 and pro-
tocol 2, respectively. The other two slides in each batch were used to stain singleplex PD-L1
and FoxP3, respectively. The images were acquired with a Vectra 3.0 Automated Quantitative
Pathology Imaging System and quantification analysis was done using InForm Advanced
Image Analysis Software (PerkinElmer) under the guidance of a board-certified pathologist.
Human tissue collection, processing, and quantification analysis
Primary human tumor specimens from patients with head and neck squamous cell carcinoma
(HNSCC; n = 10), non-small cell lung cancer (NSCLC; n = 12), or breast cancer (BCa; n = 10)
were collected following standard-of-care surgical resection at the Providence Cancer Institute.
Specimens were collected following informed consent and the study was approved by the
Providence Health System Regional Institutional Review Board–Oregon (IRB#06–108). Tis-
sues were fixed and embedded using standard clinical protocols at the Histopathology Lab.
4μm-thin sections were used for staining and mIHC images were acquired using a Vectra 3.0
Automated Quantitative Pathology Imaging System. Quantification analysis was done using
InForm Advanced Image Analysis Software under the guidance of a board-certified patholo-
gist. One-way ANOVA was used to compare overall differences among the groups. All statisti-
cal analyses were performed using GraphPad Prism software (GraphPad, San Diego, CA). A p-
value of<0.05 was considered significant.
Results
Antibody validation and balancing antigen retrieval among multiple
antibodies/biomarkers
HIAR and Tris-EDTA buffer pH9.0 were recommended (based upon vendor’s data sheets) for
antigen retrieval of CD163, CK, and PD-L1 in human FFPE tissue sections. Using chromo-
genic IHC, we optimized the titrations of these three antibodies by following the
PLOS ONE Improved 7-color multiplex IHC panel
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manufacturer’s instructions. A 1:4 dilution for anti-CD163, 1:3000 for anti-CK, and 1:1600 for
anti-PD-L1 provided consistent staining in tonsil tissue sections (Fig 1A–1C). We used 1X
TBST to replace primary or secondary antibodies on the adjacent tissue sections as a control.
However, HIAR with citrate buffer pH6.0, rather than Tris-EDTA pH9.0, has been recom-
mended by the vendors for antigen retrieval of CD3, CD8, and FoxP3 in human FFPE tissue.
Thus, the quality control (QC) tests and optimization of those antibodies were done using cit-
rate buffer pH6.0 for antigen retrieval and subsequent IHC staining. Therefore, we validated
each antibody by following the vendor’s protocol prior to optimization. We obtained consis-
tent staining for CD3, CD8, and FoxP3 with a 1:50 working dilution (Fig 1D, 1E and 1F).
Even though citrate buffer pH6.0 has been suggested for antigen retrieval of CD3, CD8, and
FoxP3, it does not preclude the use of alternative HIAR buffers for those antibodies. Since our
panel was composed of 6 biomarkers, we sought to balance the different antigen retrieval
methods in order to select one that would work for all markers. Temperature, pH, and the
heating time have been identified as the most important factors for heat-induced antigen
retrieval in human FFPE tissue [11, 12, 19, 21]. Various methods including a microwave oven,
pressure cooker, water bath, or autoclave can be used for heating the tissue and can achieve
Fig 1. Antibody validation. Anti-CD163, CK, and PD-L1 were validated using the vendor’s provided antigen retrieval method Tis-EDTA (pH 9.0)
as an antigen retrieval buffer (A, B, C). Anti-CD8, CD3, and FoxP3 were validated using the vendor’s suggested citrate buffer (pH 6.0) or Tris-EDTA
(pH 9.0) in adjacent tissue sections (D-I). The frequency (mean+/-SD) of each biomarker was determined (D-I).
https://doi.org/10.1371/journal.pone.0247238.g001
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similar results on antigen retrieval by optimizing the heating time and temperature. In the cur-
rent study, we used a microwave oven to heat human FFPE tissue sections.
Previous work has suggested that antigen retrieval buffers with higher pH give better results
than more widely used lower pH buffers, such as citrate buffer, pH6.0 [12]. We decided to test
Tris-EDTA pH9.0 on antigen retrieval of CD3, CD8, and FoxP3 epitopes. Citrate buffer pH6.0
was used for retrieving antigens in adjacent slides in parallel. We found that a 1:400 dilution
works for anti-CD8 using Tris-EDTA buffer pH9.0, which was comparable with 1:50 dilution
using citrate buffer pH6.0 (Fig 1D and 1G). A 1:600 dilution of anti-CD3 with Tris-EDTA
buffer pH9.0 was comparable with 1:50 dilution with citrate buffer pH6.0 (Fig 1E and 1H) and
a 1:400 dilution of anti-FoxP3 with Tris-EDTA buffer pH9.0 was comparable with a 1:50 dilu-
tion with citrate buffer pH6.0 (Fig 1F and 1I). To further understand these two antigen
retrieval methods, we conducted quantification analysis on the entire tissue section using
QuPath Quantative Pathology & Bioimage Analysis [20]. The average positive cell population
and standard deviation was shown at the bottom right corner of each image (Fig 1D–1I).
Together, these results suggested that Tris-EDTA buffer pH9.0 works well on retrieving those
three antigens by optimizing antibody working concentrations. These data also verified that
using antigen retrieval buffer with a high pH value (pH8.0–9.0) allows for robust staining with
less antibody [12]. Moreover, previous work has shown that when seven different antigen
retrieval solutions at different pH values ranging from 1 to 10 were compared, it was shown
that the staining intensity was highest at pH8-9 among the three patterns of pH-influenced
antigen retrieval staining [12]. Based on these results, Tris-EDTA buffer pH9.0 was used to
retrieve all six antigens in the subsequent mIHC panels.
Opal singleplex IHC validation
We validated and optimized the titrations of the above six antibodies using chromogenic stain-
ing in human FFPE tonsil tissue sections. Then, we tested whether the TSA Opal fluorescent
stain was comparable with the corresponding chromogenic stain using 6 pairs of adjacent
(consecutive) human tonsil sections to perform chromogenic and fluorescent staining in paral-
lel. By comparing the results in adjacent/consecutive sections, we found that the singleplex
Opal fluorescent stain was comparable with its chromogenic IHC stain in adjacent sections
(Fig 2). To further understand these two singleplex IHC stainings, we did quantification analy-
sis on the entire tissue sections using QuPath Quantative Pathology & Bioimage Analysis [21].
The average positive cell population and standard deviation of each biomarker was shown at
the bottom right corner of each image (Fig 2). These data suggested that we could transfer the
singleplex IHC to Opal mIHC panel comprised of PD-L1, CD163, CD8, CK, CD3, FoxP3, and
DAPI.
The comparison of mIHC with two different staining sequences
Since Tris-EDTA buffer pH9.0 has been tested and validated on the above-mentioned markers
using the singleplex IHC stain, we used this buffer for antigen retrieval of PD-L1, CD163,
CD8, CK, CD3, and FoxP3 prior to the sequential mIHC stain. This buffer was also used by
others to develop a TSA-Opal mIHC panel [12, 22]. Citrate buffer pH6.0 was used to strip anti-
bodies in developing this multiplex IHC panel with two different staining sequences on
human FFPE tonsil tissue sections. To answer the question of whether the staining sequence
affects the signal intensity of each biomarker in mIHC, we developed two protocols with dif-
ferent staining sequences: 1) PD-L1/CD163/CD8/CK/CD3/FoxP3/DAPI; and 2) FoxP3/
CD163/CD8/CK/CD3/PD-L1/DAPI. The schematic diagram shows the main steps of the two
protocols (Fig 3A; see Methods for detailed information). The multiplex and single-color
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Fig 2. Chromogenic vs. Opal: Validation of singleplex Opal fluorescent stains in human FFPE tonsil tissue
specimens. The optimized titrations of primary antibodies (CD8, CD163, CD3, FoxP3, PD-L1, and CK) which used
Tris-EDTA pH9.0 to retrieve antigens in singlepex chromogenic stain were transferred to Opal fluorescent stain on the
adjacent slides. The frequency (mean+/-SD) of each biomarker was determined.
https://doi.org/10.1371/journal.pone.0247238.g002
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images obtained from these two protocols showed specific staining with low background of
each individual biomarker in human FFPE tonsil tissue sections (S1 Fig; H&E images of adja-
cent slides depict tissue morphology).
To dissect better the staining specificity and intensity of each individual biomarker
obtained following use of the above two mIHC protocols, we analyzed PD-L1 and FoxP3
expression as these represent primarily membrane (PD-L1) and nuclear (FoxP3) staining,
respectively. We found that anti-PD-L1 staining in each mIHC image (from serial sections)
was comparable with its corresponding singleplex stain in the adjacent slide regardless of
whether it was stained first or last in the sequential mIHC stain (Fig 3B and 3C). To further
understand these two mIHC protocols, we did quantification analysis of these two biomarkers
using InForm software. We chose 15 regions of interest (ROIs) in the mIHC tissue slide and
15 corresponding ROIs in adjacent singleplex IHC tissue slides following pathology review.
Cell phenotyping and scoring data were used to decide PD-L1+ populations due to the wide
range of PD-L1 expression and the threshold of PD-L1 positivity was determined based upon
pathology review. The percentage of PD-L1+ cells in each corresponding ROI was used to
compare between mIHC and singleplex PD-L1 stains. We found the percent of PD-L1+ popu-
lation obtained in 15 ROIs in mIHC slide following staining with Protocol 1 was correlated
with the corresponding ROIs in singleplex PD-L1 slide. Linear Regression analysis was shown
a significant correlation (Fig 4A and 4B). Similar analysis was done in another pair of mIHC
by following Protocol 2 and singleplex IHC tissue slides and the percent PD-L1+ population
obtained with mIHC was also very similar to the corresponding ROIs in the singleplex PD-L1
slide (Fig 4C and 4D).
We conducted a similar comparison of FoxP3 expression. When FoxP3 was stained first in
the mIHC panel, the percent positive cell population was correlated with the corresponding
ROIs in the consecutive singleplex IHC tissue slide (Fig 4F), as we observed for PD-L1
Fig 3. Comparison of staining sequences for mIHC. Schematic diagrams show two protocols with different staining sequences (A). Multiplex IHC and single
color images were obtained using these two protocols from human tonsil (FFPE) tissue serial sections. H&E images show the morphology (B, C). Singleplex
IHC in adjacent slides verified individual biomarker stains in mIHC (B, C). The mIHC stain followed Protocol 1 in (B) and Protocol 2 in (C).
https://doi.org/10.1371/journal.pone.0247238.g003
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staining. When FoxP3 was stained last in the sequential mIHC, the percent positive cell popu-
lation was correlated with the corresponding ROIs of the singleplex FoxP3 slide as well (Fig
4E). Together, these data suggested that the staining sequence does not affect the staining
Fig 4. Quantification analysis on PD-L1+, FoxP3 +, CD3+CD8+, and CD3+FoxP3+ cell populations. Quantification analysis confirmed the percent PD-L1+
cell population determined by mIHC is comparable with singleplex IHC in the adjacent sections (A-D). The threshold of PD-L1+ cell populations was
determined by a Board-certificated Pathologist. The staining intensity of PD-L1 cells above the threshold were recognized as positive cells. The mIHC stain
followed Protocol 1 in (A) and Protocol 2 in (C). Similar analysis was conducted with respect to FoxP3 expression (E, F). CD3+CD8+ and CD3+FoxP3+ cell
populations stained by Protocol 1 and Protocol 2 were analyzed (G, H).
https://doi.org/10.1371/journal.pone.0247238.g004
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intensity of each individual marker in this mIHC panel as long as Tris-EDTA buffer pH9.0
was suitable for antigen retrieval and citrate buffer pH6.0 as a stripping buffer. CD3+CD8+ and
CD3+FoxP3+ cell populations were quantified, respectively, to determine the extent to which
the staining sequence affects detection of these epitopes. Linear Regression Analysis data was
shown the highly significant correlation between these two protocols (Fig 4G and 4H), demon-
strating that the staining sequence does not affect detection of these populations.
Evaluation of mIHC staining and extent of tumor infiltrating lymphocytes
(TIL) in breast cancer, head and neck cancer, and non-small cell lung
cancer tissue specimens
After we optimized the mIHC protocols on human FFPE tonsil tissue specimens, we tested
this panel across several different cancer types. The profile of tumor infiltrating lymphocytes
(TILs) and the immune checkpoint inhibitor PD-L1 was examined in head and neck squa-
mous cell carcinoma (HNSCC), breast cancer (BCa), and non-small cell lung cancer (NSCLC)
specimens obtained from primary surgical resections. We stained NSCLC (n = 15), HNSCC
(n = 10), and BCa (n = 12) specimens with Protocol 1 (see representative mIHC images and
H&E images of adjacent slides in Fig 5A and Table 2). Quantification analysis was done on
ROIs (n = 10/slide) and different cell populations including CD3+, CD8+, CD163+, FoxP3+,
PD-L1+, and CK+ were analyzed in stromal (CK-) and tumor (CK+) areas, respectively. The
median from all ROIs per patient was used for comparison cross tumor types. This analysis
revealed a statistically significant increase in the CD3+ population within the stromal area of
NSCLC as compared to BCa (Fig 5B), which reflects the low level of immune infiltration typi-
cally observed in ER+, PR+, and/or HER2+ breast cancer [23–25]. No significant differences
were observed with respect to CD8+ T cells, CD163+ macrophages, or FoxP3+ regulatory T cell
infiltration across the tumor types (Fig 5B). Further analysis revealed significantly greater
PD-L1 expression within CK+ tumor cells, but not stroma, in HNSCC tissue as compared to
BCa (Fig 5C). Taken together, these data demonstrate the utility of this panel for investigation
of immune infiltration of several different primary human tumors.
Discussion
Conventional mIHC involves incubation of antibody cocktails on a single tissue slide, which
requires those antibodies to be raised in different species of animals. Due to this hurdle, it has
been very difficult to get robust staining of multiple biomarkers within a single tissue section
using traditional methods. The Opal mIHC method [9] uses tyramide, which covalently binds
to the same protein of the antigen or the nearby proteins, to amplify the signal. The primary
and secondary antibodies can then be stripped away by heating the slides in citrate buffer
pH6.0 in a microwave oven. This makes similar species of antibodies amenable for sequential
staining of a single tissue section.
However, to ensure proper staining for each biomarker in a multiplex IHC panel, it is cru-
cial to choose the appropriate antigen retrieval buffer/method for the majority of or all bio-
markers within the panel. This is especially important in mIHC panels where different antigen
retrieval buffers/methods are recommended by the vendor for each of the antibodies. The first
issue to consider is choosing the proper antigen retrieval method. The pH value is more critical
than the chemical composition of the antigen retrieval buffer solution [12]. Indeed, antigen
retrieval buffers with higher pH value (such as Tris-EDTA pH9.0) are more advantageous than
citrate buffer pH6.0 [12]. In our study, this was verified with the staining of CD8, CD3, and
FoxP3 (Fig 1G–1I).
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Since Tris-EDTA buffer pH9.0 is more effective in retrieving antigens than citrate buffer
pH6.0, the working concentrations of the primary antibodies needs to be reduced when choos-
ing this buffer for retrieving antigens (Fig 1D–1I). Our method defined a standard procedure
to find the optimal titration using conventional chromogenic staining for TSA-Opal IHC. The
working concentration of primary antibody we obtained by incubation at 4˚C overnight
worked very well for all the biomarkers in our panels, as opposed to the vendor-suggested
incubation conditions (e.g., CD8 incubation at RT for 30 min).
Table 2. Patient demographics.
Number of patients (n) Age range (years; mean±SD) Gender (M/F) HPV (p16) status (pos/neg/ND)
NSCLC 15 40–81 (67.5±11.2) 5/10 N/A
HNSCC 10 51–80 (63±10.1) 7/3 5/3/2
BCa 12 35–90 (69.8±18.8) 0/12 N/A
NSCLC (non-small cell lung cancer); HNSCC (head and neck squamous cell carcinoma);
BCa (breast cancer); ND (not determined); N/A (not applicable)
https://doi.org/10.1371/journal.pone.0247238.t002
Fig 5. mIHC staining and analysis of immune infiltration of HNSCC, NSCLC, and BCa specimens. The protocol was validated in head and neck cancer
(HNSCC), non-small cell lung cancer (NSCLC), and breast cancer (BCa) patient samples. H&E images show the morphology (A). Different cell populations
were compared among different cancer types including T cells (CD3+ or CD8+), Treg (FoxP3+), and PD-L1+ tumor cells. The median of each patient from all
available ROI was used for analysis (B, C). Graphs depict the mean+/-range from all patients within each cohort. ��P<0.01 (1-way ANOVA).
https://doi.org/10.1371/journal.pone.0247238.g005
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To facilitate panel development, we selected specific antibodies and clones that are used for
clinical assessment by our Department of Pathology including CD3, CD8, CD163, and CK.
The specificity and titers were tested on control FFPE tissues including human tonsil (CD3,
CD8, CD163, FoxP3, and CK) and placenta (PD-L1). The proper titrations of each antibody
was obtained by serial dilution tests on contiguous sections as previously described [26]. Stan-
dard controls including mouse or rabbit IgG and staing in the absence of primary or secondary
antibody were used to assess antibody specificity and background. All control staining was
reviewed by the pathologist (S2 Fig). The singleplex PD-L1 chromogenic stain was compared
with the staining obtained from the clinical PD-L1 assay (clone sp263) and staining results
were comparable [12, 27].
Previous reports noted the difference in signal amplification between conventional chro-
mogenic and TSA-Opal IHC [12, 22, 28], however no staining protocol was provided detailing
how to ensure optimal TSA-Opal staining intensity comparable with chromogenic staining. In
another study, automated singleplex chromogenic staining, manual singleplex IHC, and man-
ual mIHC staining were performed in developing 7-color mIHC panels [12, 29]. However, this
protocol and the staining conditions used therein are difficult to compare as the staining con-
ditions provided by the autostainer are different from the manual procedure. Furthermore,
how one would transfer the antibody titrations used in chromogenic staining to IF stain was
not addressed [12, 29]. When we evaluated the singleplex fluorescence staining on the adjacent
slide to the chromogenic stain, the working concentration of primary antibodies was exactly
same for each approach (Fig 2). One difference was the antibody incubation time was much
shorter than the chromogenic stain, likely due to the robust signal enhancement provided by
the TSA-mediated amplification, as previously reported [12, 22, 28].
For fluorescence staining, if the primary antibody was incubated overnight at 4˚C, we
observed that the fluorescent signal was too strong. We have optimized several additional
markers using this approach and successfully transferred these to various mIHC panels. It
should be noted that if one follows the vendor-suggested incubation conditions, then the titra-
tion is typically too high for TSA-Opal and can be difficult to strip, which may result in signifi-
cant fluorophore overlap in subsequent mIHC panels (S3 Fig). When Tris-EDTA pH9.0 is
selected for antigen retrieval, we recommended using citrate buffer pH6.0 for stripping, but
not Tris-EDTA pH9.0. Heating time is the one of the most important factors which influence
HIAR [12, 30]. In terms of our results of Fig 1D–1I, apparently Tris-EDTA pH9.0 is more
harsh comparing with cirtrate buffer pH6.0, which is consistent with previous reports [12, 30].
This same group found that maximal retrieval using a microwave oven was obtained with a 20
min exposure for most commonly used antibodies [12, 30]. In addition multiple groups collab-
orated to optimizing HIAR for estrogen receptor detection and found that the optimal time
for antigen retrieval was 15 to 25 min. Artifacts and diminished staining appear at 30 min after
keeping a plateau [12, 31].
If choosing Tris-EDTA pH9.0 for retrieving antigens and stripping antibodies before stain-
ing the next biomarker in mIHC, excessive antigen retrieval may cause artifacts or diminished
staining of some, if not all, biomarkers, after the first epitope, thus highlighting the importance
of the staining sequence [12, 22]. Similarly, we do not recommend using citrate buffer pH6.0
for antigen retrieval prior to staining and stripping antibodies during the mIHC staining pro-
tocol. If we did not balance the antigen retrieval for all the biomarkers in the panel, but just fol-
lowed the vendor’s recommendation on the antigen retrieval such as citrate buffer pH6.0 for
CD3, CD8, FoxP3 and Tris-EDTA pH9.0 for CD163, CK, PD-L1, then the individual biomark-
ers may exhibit different intensities when the staining sequence is changed. For example, in
one study exploring 7-color mIHC protocol development, Tris-EDTA was chosen for retriev-
ing antigens for CD3, CD4, granzyme B, and CD57 singleplex IF staining. Citrate buffer was
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chosen for PD-L1 and CK staining [12, 29]. Then those antigen retrieval conditions (for all 6
biomarkers) were transferred to the mIHC protocol without balancing antigen retrieval and
antibody stripping methods. Notably, when the staining sequence is changed, the intensity of
staining for individual biomarkers will be altered, which may explain why the authors pro-
vided a “best sequence” of antibodies for this mIHC panel [12, 29]. However, the authors did
not provide a method to resolve this problem.
Importantly, when developing a new panel with multiple biomarkers, although vendor-sug-
gested antigen retrieval methods can be used for antibody validation, it does not mean that
other antigen retrieval methods aren’t suitable. Rather, these alternative methods were likely
not evaluated during the original production and/or validation of the antibody. In reality,
most of the antibodies effective for staining human FFPE tissue, especially those for in vitro
diagnostic use, work well with Tris-EDTA pH9.0. However, there are always exceptions and if
one antibody in the panel works only with citrate buffer pH6.0, then this antibody should be
stained first. The same strategy works for enzyme induced epitope retrieval (EIER), though we
do not recommend using this method for mIHC (manuscript in preparation).
Quantification analysis of PD-L1+, FoxP3+, CD3+CD8+, and CD3+FoxP3+ cell populations
in human FFPE tonsil tissue verified that the staining sequence does not affect the staining
intensity as long as the proper antigen retrieval method was used before mIHC. When PD-L1
was stained first by following Protocol 1, the percent of PD-L1+ cells was the same or slightly
lower as compared to the singleplex PD-L1 stain on the adjacent slide (Fig 4B). When FoxP3
was stained first (Protocol 2), the percent of FoxP3+ cells was the same or slightly lower as
compared to the singleplex FoxP3 stain on the adjacent slide (Fig 4F). The positive cell popula-
tions of these two biomarkers showed the same pattern in mIHC compared to adjacent single-
plex staining. Linear Regression Analysis revealed a strong correlation between mIHC and
singleplex staining (Fig 4B and 4F). When PD-L1 was stained just before DAPI by following
Protocol 2, the percent PD-L1+ was comparable with singleplex PD-L1 stain on the adjacent
slide (Fig 4D). We obtained similar results when FoxP3 was stained just before DAPI (Protocol
1; Fig 4E). There are three potential sources of variation in these data: 1) the stripping steps
during the mIHC stain may affect the final cell counts; 2) due to variable expression of PD-L1
and the potential for signals from other fluorophores to cross into the same filter, detection of
cells with low staining intensity cells during image acquisition can be variable; and 3) the cell
segmentation process during quantification analysis may slightly differ each time it is applied
to the image, which may contribute to the variation.
When we developed these mIHC protocols, we started by testing the quality of the primary
antibodies through validating the mIHC protocols with manual staining, but not with an auto-
mated system. One key finding from our study is that we have provided an easy to follow and
repeatable procedure on how to get consistent and reliable staining for each individual bio-
marker in the mIHC panel, regardless of the staining sequence. In some published studies,
automated and manual staining protocols are combined when developing the multiplex IHC
protocol. Indeed, using automated equipment for standard chromogenic IHC is the standard
process for most diagnostic labs. However, it is often difficult for research labs to use both
approaches as automated staining platforms may not be readily accessible.
To our knowledge, few, if any, studies have examined the impact of antigen retrieval meth-
ods and staining sequence on the generation of optimal mIHC data using the TSA-based kit.
Our study has focused on balancing antigen retrieval within the mIHC panel to determine
which antigen retrieval buffer works best for the whole panel. We recommend using high pH
solutions such as Tris-EDTA pH9.0 to retrive epitopes and citrate buffer pH6.0 to strip anti-
bodies. This criteria can be used to develop any mIHC panel on human FFPE tissue sections as
long as HIAR is required for all the biomarkers within the panel. To date, we have developed
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and validated 9 mIHC panels which we are utilizing for biospecimen analysis from multiple
clinical trials. Similarly, these protocols can be transitioned to an automated staining platform
using these criteria. Indeed, we have successfully transferred our protocols to an autostainer.
Additional antigen retrieval solutions with high pH will be tested in our lab in the near future.
In our protocols, Tris-EDTA buffer pH9.0 was used for retrieving antigens, while citrate
buffer pH6.0 was used for stripping antibodies. The primary antibodies (mouse and rabbit)
were used for mIHC and stained alternately. Mouse or rabbit HRP only, but not mouse and
rabbit combined HRP, was used as a secondary antibody which enables 3% H2O2 to be used at
RT for inactivating exogenous HRP. This helps maintain tissue integrity better than stripping
in a microwave oven (2x instead of 5x stripping in our protocols) especially for high adipose
tissues, such as breast tissue. This also decreases heat accumulation in the tissue section, which
may cause degradation of antigens in the nuclei. It also suggests that selecting different species
of the primary antibodies may be especially beneficial for some tissue types or some biomark-
ers when developing mIHC protocols.
To ensure exogenous HRP is completely inactivated by 3% H2O2 and that there is no carry-
over signal before staining the next biomarker, we optimized the procedure by using a differ-
ent Opal fluorophore for re-detection until no more signals were found [12, 15]. For example,
after anti-CD3-Opal540 was stained on two serial sections of tonsil tissue following Protocol 1,
3% H2O2 incubation was performed for 10 and 30 min, respectively, at RT followed by incuba-
tion with Opal650. We found no signals were detected by Opal650 on the slide incubated with
3% H2O2 for 30 min at RT (S4 Fig). This data suggested that 30 min incubation at RT was suffi-
cient to inactivate exogenous HRP caused by CD3 stain. A similar method was used to opti-
mize antibody stripping steps with citrate buffer.
Also, we found that when scanning the whole slide and obtaining MSI images/ROIs, an
optimized scanning protocol for each individual mIHC slide was necessary. Sharing protocols
often led to overexposed or diminished signals since fluorescence (TSA-Opal) is much more
sensitive than brightfield imaging. Fluorescent mIHC images allow in situ identification of dif-
ferent immune cell populations on one single section [9]. Recently, we performed 7-color
mIHC on specimens from an early-stage breast cancer immunotherapy clinical trial. In this
study, we verified how mIHC can be used to precisely estimate dynamic changes in tumor-
infiltrating lymphocytes (TILs) score, PD-L1 expression, and other immune variables from a
single FFPE section. These data helped provide insight into the spatial characteristics of the
tumor microenvironment following immunotherapy treatment [27]. Our quantification analy-
sis results revealed the differential expression of several immune cell populations across differ-
ent cancer types. In this panel, PD-L1 (immune checkpoint), CD3 (T cells), CD8 (cytotoxic T
cells), CD163 (histiocytes/macrophages), and FoxP3 (regulatory T cells) were analyzed in epi-
thelial tumor (CK+) and surrounding stromal (CK-) compartments, respectively, across 3 dif-
ferent tumor types (Fig 5). Our initial analysis revealed significant increases in CD3+ T cell
accumulation in the stroma in NSCLC as compared to BCa specimens (Fig 5B) and increased
PD-L1 expression in HNSCC tumors compared to BCa (Fig 5C). We found that a small popu-
lation of CD3-CD8+ cells across different tumor types. These cells could be a subpopulation of
natural killer cells as CD3-CD8+ and CD3-CD8+CD16+CD56+ cells have been identified in
peripheral blood [12, 32, 33]. To confirm this cell population, a new mIHC panel including
CD3, CD8, CD16 and CD56 is under development in our lab. Future analyses are planned,
including characterization of the spatial relationships between effector (CD8+) and suppressive
(FoxP3+ or PD-L1+) cell subsets across the various tumor types and correlations with clinical
outcomes, such as tumor recurrence.
Currently, 8 biomarkers can be stained together using the TSA-Opal system and the advan-
tages and disadvantages of this method were recently reviewed [34]. There is concern
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regarding adding >8 markers to the panel as overheating the tissue may to excessive epitope
retrieval and eventually loss of signal with consecutive rounds of staining. Thus, if additional
biomarkers need to be stained on a single slide, alternative mIHC techniques are likely more
appropriate, such as Imaging Mass Cytometry or use of the GeoMx Digital Spatial Profiler,
which take advantage of mass spectrometry-based methods to interrogate the expression of
multiple biomarkers simultaneously. These methods have disadvantages as well, including spe-
cialized equipment, high cost to stain each slide, and requirement for specialized bioinformat-
ics support for data management and analysis.
In summary, we have investigated several critical parameters required to obtain high-qual-
ity mIHC images, particularly antigen retrieval methods. We believe these data would provide
a framework that will enable more robust and consistent mIHC staining in the research lab
setting.
Supporting information
S1 Fig. Merged and single biomarker stained by Protocol 1 and Protocol 2.
(TIF)
S2 Fig. CD3 (rabbit) and CK (mouse) staining with corresponding controls.
(TIF)
S3 Fig. High titer anti-PD-L1 stain caused signal crossover with CD3. The circled cells are
PD-L1+ CD3- cells.
(TIF)
S4 Fig. Optimization of 3% H2O2 incubation to inactivate exogenous HRP. Incubation with
3% H2O2 for 30 min at RT was sufficient to inactivate exogenous HRP caused by CD3 stain
(compare S3F vs. S3C).
(TIF)
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15. Tóth ZE, Mezey E. Simultaneous visualization of multiple antigens with tyramide signal amplification
using antibodies from the same species. J Histochem Cytochem. 2007; 55(6):545–54. Epub 2007/01/
24. https://doi.org/10.1369/jhc.6A7134.2007 PMID: 17242468.
PLOS ONE Improved 7-color multiplex IHC panel
PLOS ONE | https://doi.org/10.1371/journal.pone.0247238 February 17, 2021 19 / 21
16. Mason JT FC, O’Leary TJ. Study of Formalin-Fixation and Heat-Induced Antigen Retrieval. In: Shi S-R
TC, editor. Antigen Retrieval Immunohistochemistry Based Research and Diagnostics: John Wiley &
Sons; 2010. p. 253–85.
17. Bogen SA SS. A Linear Epitopes Model of Antigen Retrieval. In: Shi S-R TC, editor. Antigen Retrieval
Immunohistochemistry Based Research and Diagnostics: John Wiley & Sons; 2010. p. 287–302.
18. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry used for routinely processed celloi-
din-embedded human temporal bone sections: standardization and development. Auris Nasus Larynx.
1998; 25(4):425–43. Epub 1998/12/16. https://doi.org/10.1016/s0385-8146(98)00042-x PMID: 9853668.
19. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histo-
chem Cytochem. 1997; 45(3):327–43. Epub 1997/03/01. https://doi.org/10.1177/
002215549704500301 PMID: 9071315.
20. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open
source software for digital pathology image analysis. Sci Rep. 2017; 7(1):16878. Epub 2017/12/06.
https://doi.org/10.1038/s41598-017-17204-5 PMID: 29203879; PubMed Central PMCID:
PMC5715110.
21. Evers P, Uylings HB. Effects of microwave pretreatment on immunocytochemical staining of vibratome
sections and tissue blocks of human cerebral cortex stored in formaldehyde fixative for long periods. J
Neurosci Methods. 1994; 55(2):163–72. Epub 1994/12/01. https://doi.org/10.1016/0165-0270(94)
90208-9 PMID: 7723380.
22. Gorris MAJ, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe IN, Verweij D, et al. Eight-Color
Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules
within the Tumor Microenvironment. Journal of immunology. 2018; 200(1):347–54. Epub 2017/11/17.
https://doi.org/10.4049/jimmunol.1701262 PMID: 29141863.
23. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs)
improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015; 4(9):
e985930. https://doi.org/10.4161/2162402X.2014.985930 PMID: 26405612; PubMed Central PMCID:
PMC4570112.
24. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-
infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working
Group 2014. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO.
2015; 26(2):259–71. Epub 2014/09/13. https://doi.org/10.1093/annonc/mdu450 PMID: 25214542;
PubMed Central PMCID: PMC6267863.
25. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+
lymphocytes predict clinical outcome in breast cancer. Journal of clinical oncology: official journal of the
American Society of Clinical Oncology. 2011; 29(15):1949–55. https://doi.org/10.1200/JCO.2010.30.
5037 PMID: 21483002.
26. Bobrow MN, Litt GJ, Shaughnessy KJ, Mayer PC, Conlon J. The use of catalyzed reporter deposition
as a means of signal amplification in a variety of formats. J Immunol Methods. 1992; 150(1–2):145–9.
Epub 1992/06/24. https://doi.org/10.1016/0022-1759(92)90073-3 PMID: 1613251.
27. Sanchez K, Kim I, Chun B, Pucilowska J, Redmond WL, Urba WJ, et al. Multiplex immunofluorescence
to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Breast Cancer Res. 2021; 23(1):2. Epub 2021/01/09. https://doi.org/10.1186/s13058-020-01378-4
PMID: 33413574; PubMed Central PMCID: PMC7788790.
28. Anyaegbu CC, Lee-Pullen TF, Miller TJ, Abel TN, Platell CF, McCoy MJ. Optimisation of multiplex
immunofluorescence for a non-spectral fluorescence scanning system. Journal of immunological meth-
ods. 2019; 472:25–34. Epub 2019/06/11. https://doi.org/10.1016/j.jim.2019.06.011 PMID: 31181211.
29. Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA, et al. Validation of multiplex immunofluo-
rescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-
embedded human tumor tissues. Sci Rep. 2017; 7(1):13380. Epub 2017/10/19. https://doi.org/10.1038/
s41598-017-13942-8 PMID: 29042640; PubMed Central PMCID: PMC5645415.
30. Taylor CR, Shi SR, Chen C, Young L, Yang C, Cote RJ. Comparative study of antigen retrieval heating
methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem.
1996; 71(5):263–70. Epub 1996/09/01. https://doi.org/10.3109/10520299609117171 PMID: 8896801.
31. Balaton AL, Coindre JM, Collin F, Ettore F, Fiche M, Jacquemier J, et al. [Recommendations for the
immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study
Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of
Centres to Combat Cancer/French Association for Quality Assurance in Pathology]. Ann Pathol. 1996;
16(2):144–8. Epub 1996/01/01. PMID: 8767687.
32. Simpson RJ, Florida-James GD, Cosgrove C, Whyte GP, Macrae S, Pircher H, et al. High-intensity
exercise elicits the mobilization of senescent T lymphocytes into the peripheral blood compartment in
PLOS ONE Improved 7-color multiplex IHC panel
PLOS ONE | https://doi.org/10.1371/journal.pone.0247238 February 17, 2021 20 / 21
human subjects. J Appl Physiol (1985). 2007; 103(1):396–401. Epub 2007/03/24. https://doi.org/10.
1152/japplphysiol.00007.2007 PMID: 17379755.
33. Campbell JP, Guy K, Cosgrove C, Florida-James GD, Simpson RJ. Total lymphocyte CD8 expression
is not a reliable marker of cytotoxic T-cell populations in human peripheral blood following an acute bout
of high-intensity exercise. Brain Behav Immun. 2008; 22(3):375–80. Epub 2007/10/24. https://doi.org/
10.1016/j.bbi.2007.09.001 PMID: 17949944.
34. Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, et al. The Society for Immunother-
apy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluo-
rescence (IF) staining and validation. Journal for immunotherapy of cancer. 2020; 8(1). Epub 2020/05/
18. https://doi.org/10.1136/jitc-2019-000155 PMID: 32414858; PubMed Central PMCID: PMC7239569.
PLOS ONE Improved 7-color multiplex IHC panel
PLOS ONE | https://doi.org/10.1371/journal.pone.0247238 February 17, 2021 21 / 21
